17.11  0.82 (5.03%)		09-18 16:00
Open: 16.57 High: 17.255 Volume: 6,047,297		Pre. Close: 16.29 Low: 16.27 Market Cap: 140(M)

Short term
Mid term
Targets	6-month :	20.15	1-year :	23.53
Resists	First :	17.25	Second :	20.15
Pivot price	15.5
Supports	First :	13.65	Second :	11.43
MAs	MA(5) :	15.54	MA(20) :	15.11
	MA(100) :	12.1	MA(250) :	11.93
MACD	MACD :	0.8	Signal :	0.8
%K %D	K(14,3) :	66	D(3) :	47.3
RSI	RSI(14): 69.3
52-week	High :	17.25	Low :	9.94

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FRNM ] has closed below upper band by 2.8%. Bollinger Bands are 85.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 46 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	17.28 - 17.34	17.34 - 17.41
Low:	16.1 - 16.18	16.18 - 16.26
Close:	16.98 - 17.1	17.1 - 17.23

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).

Fri, 18 Sep 2026
Freenome, Inc. Common stock (NASDAQ: FRNM) Share Price, FRNM Stock News, FRNM Share Price & Updates - Kalkine

Fri, 28 Aug 2026
Freenome, Inc. SEC Filing (Aug 28, 2026) - Stock Titan

Wed, 19 Aug 2026
Jefferies sets strong price target on upstart cancer stock - thestreet.com

Mon, 27 Jul 2026
What is the current Price Target and Forecast for Freenome, Inc (FRNM) - Zacks Investment Research

Mon, 27 Jul 2026
Freenome went public for $300 million, then scored a huge victory with colorectal cancer test - The Business Journals

Thu, 23 Jul 2026
symbol__ Stock Quote Price and Forecast - CNN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	0 (M)
Shares Float	107 (M)
Held by Insiders	6.848e+007 (%)
Held by Institutions	26 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-2.0601e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-2 %
Return on Assets (ttm)	867.5 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	3.541e+007 %
Gross Profit (p.s.)	221.87
Sales Per Share	0
EBITDA (p.s.)	-3.65062e+008
Qtrly Earnings Growth	-2.1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-108 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-0.16

Dividend	0
Forward Dividend	445740
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.